Reducing the timeline by 30% to produce a monoclonal cell line expressing a clinical candidate bi-specific antibody

SystImmune Inc., based near Seattle (WA), has its own antibody discovery platform and their objective is to generate a single cell clone with maximal expression level of their candidate bispecific immune-oncology antibody, which is targeted to the treatment of solid tumour cancer. SystImmune’s chosen path forward to prove clonality was to introduce the Solentim Cell Metric CLD into their cell line development process. The Cell Metric can image the entire well and provide a sharp image of a single cell on Day 0 which is critical proof of a single cell and will allow for a single round of cloning.